A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance — EMPIRE-01

Insulin Resistance Syndrome Clinical Trial

Official title:
A Multicenter, Open-label, Single-arm Study With Regard to the Efficacy and Safety of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance

Status Active, not recruiting

Clinical Trial Summary

A multicenter, open-label, single-arm study with regard to the efficacy and safety of empagliflozin in patients with refractory diabetes mellitus with insulin resistance

Clinical Trial Description

To evaluate the clinical efficacy of a treatment with empagliflozin in refractory diabetes mellitus patients with insulin resistance (insulin resistance syndrome, lipoatrophic diabetes mellitus) by using the HbA1c change at Week 24 of treatment from baseline ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04018365
Study type	Interventional
Source	Kobe University
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	September 1, 2019
Completion date	October 30, 2021

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04028895` - Diagnostic Interest of the IRAP Protein (Insulin Regulated Amino Peptidase) in Insulin Resistance	N/A
Completed	`NCT03011775` - Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease	Phase 4
Completed	`NCT03716336` - Aerobic and Strength Training With Caloric Restriction on Insulin Resistance in Obese Premenopausal Women	N/A
Completed	`NCT03741686` - Effect of Konjac-mannan in Individuals With Insulin-Resistance Syndrome	Phase 2
Recruiting	`NCT04128969` - Causal Mechanisms in Adolescent Arterial Stiffness	Phase 2
Active, not recruiting	`NCT04221152` - A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 )	Phase 3